BACKGROUND: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. METHODS: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. RESULTS: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. CONCLUSIONS: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.

Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy : Data from the DA-COVID-19 registry / A. Chiricozzi, M. Talamonti, C. De Simone, M. Galluzzo, N. Gori, G. Fabbrocini, A.V. Marzano, G. Girolomoni, A. Offidani, M.T. Rossi, L. Bianchi, A. Cristaudo, M.T. Fierro, L. Stingeni, G. Pellacani, G. Argenziano, A. Patrizi, P. Pigatto, M. Romanelli, P. Savoia, P. Rubegni, C. Foti, N. Milanesi, A. Belloni Fortina, M.R. Bongiorno, T. Grieco, S. Di Nuzzo, M.C. Fargnoli, A. Carugno, A. Motolese, F. Rongioletti, P. Amerio, R. Balestri, C. Potenza, G. Micali, C. Patruno, I. Zalaudek, M. Lombardo, C. Feliciani, L. Di Nardo, F. Guarneri, K. Peris. - In: ALLERGY. - ISSN 1398-9995. - 76:6(2021), pp. 1813-1824. [10.1111/all.14767]

Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy : Data from the DA-COVID-19 registry

A.V. Marzano;P. Pigatto;
2021

Abstract

BACKGROUND: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. METHODS: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. RESULTS: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. CONCLUSIONS: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.
atopic dermatitis; COVID; SARS‐CoV; Adult; Communicable Disease Control; Humans; Italy; Pandemics; Registries; SARS-CoV-2; COVID-19; Dermatitis, Atopic
Settore MED/35 - Malattie Cutanee e Veneree
Article (author)
File in questo prodotto:
File Dimensione Formato  
ALL-9999-0.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 627.54 kB
Formato Adobe PDF
627.54 kB Adobe PDF Visualizza/Apri
all.14767.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 609.4 kB
Formato Adobe PDF
609.4 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/859882
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 16
social impact